作者：新消费主张/cici 近日，HBN母公司，即深圳护家科技（集团）股份有限公司（简称"护家科技"）向港交所主板递交上市 申请书，摩根士丹利与中金公司为联席保荐人。据招股书，护家科技此次募集资金主要用于投入研发及 产品创新，加强生产能力，提升办公环境及增强数字化运营能力，投资品牌和市场推广，全渠道销售网 络的深化拓展等。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 2019年，功效护肤品牌HBN诞生，主打"早C晚A"的护肤理念，同年推出首款核心产品α-熊果素精萃 水。所谓"早C晚A"，即早上用含有维生素C成分的护肤品提亮，晚上用含有A醇成分护肤品抗衰老。 HBN的产品分为改善型护肤品与维稳型护肤品两大类，前者主要针对皱纹、色素沉淀、暗沉等肌肤老 化及氧化损伤，后者则主要满足日常护肤需求，包括清洁、维护健康皮肤屏障及紫外线防护等。具体来 看，旗下产品包括御龄紧致系列、美白焕亮系列、修护保湿系列、基础护肤系列、控油祛痘系列五大产 品线，建议零售价介于129元至689元之间。截至2025年9月30日，品牌共有36个SPU。 2023年、2024年及202 ...

2026年1月16日，山东花物堂化妆品股份有限公司正式向港交所递交招股书，旗下品牌半亩花田拟冲 刺"港股国货个护第一股"。据公司招股书，此次募集资金主要用于渠道开发、产品营销推广及品牌建 设，加强产品研发能力，建立全球多元化人才队伍，强化数字与智能化基础设施等。 近年来，公司业绩增速可观，2025年前三季度，营收同比增长76.7%至18.95亿元，经调整净利润同比增 长197.41%至1.48亿元。然而，公司业绩增长高度依赖营销，特别是相继签约关晓彤、杨洋、迪丽热巴 及奥运冠军孙颖莎等多位兼具高人气与特定粉丝号召力的名人，并将代言人与细分产品线深度绑定。这 一策略成功为品牌带来了巨大的流量曝光与销售转化，助其快速抢占市场份额，但同时也使其销售及营 销费用高企， "重营销轻研发"下业绩高增是否可持续存疑。 面部洗护仅个位数增长 近半数收入营销、粉丝效应带来的高速增长可否持续？ 半亩花田于2010年成立于山东济南，最初经营玫瑰纯露等植物原料美妆个护用品，并陆续推出磨砂膏、 身体乳等护理产品。近年来，半亩花田踏准了渠道变革的节拍，从传统电商转型，深度拥抱小红书、抖 音等内容与社交平台，通过大规模达人种草和内容营销构 ...

Core Insights - The skincare and daily chemical industry in A-share listed companies shows a persistent trend of high gross margins and low net margins, with over 80% of companies having a gross margin above 50% and more than half having a net margin below 10% [1][2] Group 1: Financial Performance - In the first half of 2025, the top three companies by gross margin are Jinbo Biological (90.68%), Fulejia (81.47%), and Beitaini (76.01%) [2] - Despite high gross margins, over half of the selected companies have net margins below 10%, with Jinbo Biological, Fulejia, and Proya leading in net margins at 45.5%, 26.61%, and 15.41% respectively [2] Group 2: Marketing and Expenses - The high gross margin and low net margin phenomenon is closely linked to the significant marketing expenditures in the industry, with companies like Marubi Biological having a sales expense ratio as high as 56.5% [1][3] - Many companies in the skincare and daily chemical sector are spending over 40% of their revenue on marketing, indicating a highly competitive marketing environment [3] Group 3: Research and Development - The investment in R&D is significantly lower than marketing expenditures, with Marubi Biological's R&D expense ratio being only 2.3% compared to its high sales expense ratio [3] - The focus on marketing over R&D has led to severe product homogeneity, limiting innovation and the ability to meet consumer skincare needs effectively [3]

Core Insights - The skincare and daily chemical industry in A-share listed companies has shown improvement in inventory status as of the first half of 2025, with only 6 out of 14 selected companies experiencing an increase in inventory scale [1] - Among the selected companies, only 5 have inventory turnover days below 90 days, indicating potential inefficiencies in inventory management for the remaining 9 companies [1] - The inventory turnover efficiency indicators for the industry are concerning, with 6 companies showing prolonged inventory turnover days, which may suggest risks of product obsolescence or slow sales [1] Inventory Analysis - In the first half of 2025, the inventory situation improved for the skincare and daily chemical listed companies, with a notable increase in inventory scale for Jinbo Biological, which had the highest year-on-year growth [1] - Only 5 companies, including Jiaheng Home, Qingsong Co., Proya, Shanghai Jahwa, and Lafang, maintained inventory turnover days below 90, while the other 9 exceeded this threshold [1] - Companies such as Huaxi Biological and Jinbo Biological are among those with longer inventory turnover days, raising concerns about their inventory management practices [1] Market Implications - The prolonged inventory turnover days across several companies may indicate a longer time frame from production to sale, potentially leading to product expiration risks [1] - The overall inventory turnover efficiency in the skincare and daily chemical sector is not optimistic, highlighting a need for companies to improve their inventory management strategies [1]

Core Insights - The skincare and daily chemical industry in A-share listed companies has shown improvements in inventory levels as of the first half of 2025, with only 6 out of 14 selected companies experiencing an increase in inventory size [1][2] Inventory Size Analysis - Jinbo Biological had the largest year-on-year increase in inventory, reaching 153 million yuan, a growth of 116.79% compared to the first half of 2024 [1][2] - Kesheng Co. also saw significant growth, with inventory at 628 million yuan, up 40.87% year-on-year [1][2] - Other companies with notable inventory increases include Marubi Biological (35.91%), Chuang'er Biological (34.02%), and Jiaheng Home Care (31.39%) [2] Inventory Turnover Days - Among the 14 selected companies, only 5 had inventory turnover days below 90 days, indicating efficient inventory management [3] - Companies with inventory turnover days exceeding 180 days include Huaxi Biological (331.61 days), Jinbo Biological (280.81 days), Kesheng Co. (230.92 days), and Betaini (195.78 days) [3][4] - The overall inventory turnover efficiency has not improved, with 8 companies experiencing longer turnover days, particularly those exceeding 180 days [3] Year-on-Year Changes in Inventory Turnover Days - Huaxi Biological's turnover days increased by 13.34%, Jinbo Biological by 15.66%, Kesheng Co. by 115.83%, and Betaini by 0.54% [3][4] - Notably, the turnover days for LaFang Home Care decreased by 27.40%, and Shanghai Home Care by 15.74%, indicating some companies are managing their inventory more effectively [4]

Core Viewpoint - The skincare and daily chemical industry in A-share listed companies has shown improvements in inventory levels for the first half of 2025, with only six out of fourteen selected companies experiencing an increase in inventory size [1][2]. Inventory Scale Analysis - In the first half of 2025, Jinbo Biological had the largest year-on-year increase in inventory, reaching 153 million yuan, a growth of 116.79% [2]. - Kesheng Co. also saw significant inventory growth, with a total of 628 million yuan, marking a 40.87% increase [2]. - Other companies with notable inventory increases include Marubi Biological (35.91%), Chuang'er Biological (34.02%), and Jiaheng Home Care (31.39%) [2]. Inventory Turnover Days - Among the fourteen selected companies, only five had inventory turnover days below 90 days, indicating efficient inventory management [2]. - Companies with inventory turnover days exceeding 180 days include Huaxi Biological (331.61 days), Jinbo Biological (280.81 days), Kesheng Co. (230.92 days), and Beitaini (195.78 days) [2][4]. - The overall inventory turnover efficiency in the industry is concerning, with six companies showing improvement while eight companies experienced longer turnover days [3]. Year-on-Year Changes in Inventory Turnover Days - Huaxi Biological's inventory turnover days increased by 13.34%, reaching 331.61 days [4]. - Jinbo Biological's turnover days rose by 15.66% to 280.81 days [4]. - Kesheng Co. saw a dramatic increase of 115.83% in turnover days, reaching 230.92 days [4]. - Other companies like Fushijia and Shanghai Jahwa also reported changes in turnover days, with Fushijia increasing by 31.52% [4].

Core Insights - The skincare and daily chemical industry in A-shares has shown a high gross profit margin but low net profit margin, with over 80% of companies having a gross profit margin above 50% and more than half having a net profit margin below 10% [1][4] - The significant gap between gross and net profit margins is attributed to high sales expenses, which consume profits, with Marubi Biological's sales expense ratio reaching 56.5%, making it the highest in the industry [1][6] Financial Performance - The top three companies by gross profit margin in the first half of 2025 are Jinbo Biological (90.68%), Fulejia (81.47%), and Beitaini (76.01%) [2] - Only four companies reported a gross profit margin below 50%, namely Lafang, Kesi, Qingsong, and Jiaheng, with margins of 49.26%, 32.05%, 17.51%, and 14.98% respectively [2] Profitability Analysis - Despite high gross profit margins, over half of the selected companies have net profit margins below 10%, with Jinbo Biological, Fulejia, and Polaroid leading in net profit margins at 45.5%, 26.61%, and 15.41% respectively [4] - Jiaheng, Lafang, and Qingsong have low net profit margins of -6.26%, 1.58%, and 2.66% respectively [4] Marketing and R&D Expenditure - The high marketing expenses in the industry are closely linked to the high gross and low net profit margins, with many companies spending over 40% of their revenue on marketing [6][9] - Marubi Biological's sales expense ratio is 56.5%, while its R&D expense ratio is only 2.3%, indicating a heavy reliance on marketing over research and development [8] Industry Challenges - The focus on marketing over R&D has led to severe product homogeneity, limiting innovation and hindering brand development [8] - The industry faces ongoing price wars and promotional activities that further erode profitability, creating a vicious cycle [9] - Companies need to balance marketing and R&D expenditures to transition from a marketing-driven to a product-driven approach [9]

Core Insights - The skincare and daily chemical industry in A-shares has shown a high gross profit margin but low net profit margin, with over 80% of companies having a gross profit margin above 50% and more than half having a net profit margin below 10% [1][4] - The significant gap between gross and net profit margins is attributed to high sales expenses, which consume profits, with Marubi Biological's sales expense ratio reaching 56.5%, making it the highest in the industry [1][6] Group 1: Financial Performance - The top three companies by gross profit margin in the first half of 2025 are Jinbo Biological (90.68%), Fulejia (81.47%), and Beitaini (76.01%) [2] - Only four companies reported a gross profit margin below 50%, namely Lafang, Kesi, Qingsong, and Jiaheng, with margins of 49.26%, 32.05%, 17.51%, and 14.98% respectively [2] - The leading companies in net profit margin are Jinbo Biological (45.5%), Fulejia (26.61%), and Polaroid (15.41%), while Jiaheng, Lafang, and Qingsong have low margins of -6.26%, 1.58%, and 2.66% respectively [4] Group 2: Marketing and R&D Expenditure - The high marketing expenses in the industry are closely linked to the high gross profit but low net profit, with many companies spending over 40% of their revenue on marketing [6][9] - Marubi Biological's sales expense ratio is 56.5%, while its R&D expense ratio is only 2.3%, indicating a heavy reliance on marketing over research and development [8] - The focus on marketing over R&D has led to severe product homogenization, limiting innovation and hindering brand development [8][9] Group 3: Industry Challenges - The industry faces challenges in balancing marketing and R&D expenditures, with a need to shift from marketing-driven to product-driven strategies [9]

Core Insights - The skincare and daily chemical industry in A-shares has shown a high gross profit margin but low net profit margin, with over 80% of companies having a gross profit margin above 50% and more than half having a net profit margin below 10% [1][4] - The significant gap between gross and net profit margins is attributed to high sales expenses, which consume profits, with Marubi Biological's sales expense ratio reaching 56.5%, making it the highest in the industry [1][6] Financial Performance - The top three companies in terms of gross profit margin for the first half of 2025 are Jinbo Biological (90.68%), Fulejia (81.47%), and Beitaini (76.01%) [2] - Only four companies reported a gross profit margin below 50%, with figures of 49.26% for Lafang, 32.05% for Kesi, 17.51% for Qingsong, and 14.98% for Jiaheng [2] Marketing and R&D Expenditure - The industry is characterized by high marketing expenditures, with many companies spending over 40% of their revenue on marketing, leading to a focus on brand marketing over product development [6][9] - Marubi Biological's sales expense ratio is 56.5%, while its R&D expense ratio is only 2.3%, indicating a heavy reliance on marketing rather than innovation [8] Industry Challenges - The heavy emphasis on marketing has resulted in severe product homogeneity, limiting true innovation and hindering brand development [8] - The industry faces ongoing price wars and promotional activities that further erode profitability, creating a vicious cycle [9] - Companies must find a balance between marketing and R&D expenditures to transition from a marketing-driven approach to a product-driven strategy [9]

Core Insights - The 67th China (Shanghai) International Beauty Expo successfully showcased the vitality and potential of the beauty industry, emphasizing resilience, innovation, and intelligence in development [1][2] Group 1: Event Overview - The expo covered an exhibition area of 150,000 square meters, featuring over 1,800 exhibitors from more than 68 countries and regions, displaying over 10,000 selected product categories [2] - The event attracted significant foot traffic and facilitated vibrant business exchanges, highlighting the robust market activity within the beauty sector [2] Group 2: Global Expansion - The expo aimed to build a new ecosystem for diverse cooperation in the beauty industry, establishing an efficient global communication platform for sourcing and sales [3] - It gathered professional buyers from various channels, including traditional retailers and new e-commerce trends, showcasing international exhibitors from countries like South Korea, Japan, the USA, and Canada [3] - Plans for 2025 include the addition of the "Indonesia International Beauty Expo" and "Vietnam International Beauty Expo," supporting Chinese beauty brands in expanding overseas [3] Group 3: Industry Innovation - The expo focused on industry logic, uniting upstream and downstream brand forces, with new products covering multiple fields, enhancing brand competitiveness and driving technological upgrades [4] - AI technology in beauty attracted attention, while several medical beauty brands accelerated their entry into the daily skincare market [4] - The event highlighted the "Matthew Effect" in the daily chemical sector, with leading brands leveraging resources to enter professional channels [4] Group 4: Future Trends - The expo outlined a development blueprint for the beauty industry through a systematic approach of summits, activities, and special exhibitions, providing forward-looking insights [5] - Over 50 special events were held during the expo, covering topics such as beauty, health, and e-commerce, enhancing the industry's outreach and impact [5] - The event featured 15+ themed exhibition areas, showcasing innovations in professional technology, AI applications, and cross-industry segments [5] Group 5: Looking Ahead - The beauty expo is set to embark on a new journey, focusing on domestic demand and actively exploring new growth areas for Chinese beauty brands [6] - The next edition, the 68th China (Guangzhou) International Beauty Expo, is scheduled for September 4-6, 2025, in Guangzhou [6]